LTZ Therapeutics
PrivateLast Round
Series B
May 6, 2026
Total Funding Raised
$115M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
LTZ Therapeutics is a biotechnology company that develops innovative immunotherapies for cancer and autoimmune diseases using its proprietary Myeloid Engager Platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
LTZ Therapeutics Comparables
Compare LTZ Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CREATE Medicines | 81% | |
| Elpiscience Biopharmaceuticals | 79% | |
| Bolt Biotherapeutics | 78% |
LTZ Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 6, 2026 | ||||
| Series A Extension | Apr 24, 2025 | ||||
| Series A | Jul 30, 2024 | ||||
| VC Round | May 31, 2023 | ||||
| Seed | Apr 7, 2022 |
LTZ Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lanchi Ventures | Series B, Series A Extension |
| Boyu Capital | Series B, Series A Extension |
| Zoo Capital | Series A Extension |
| Hillhouse Investment | Series A, Series A Extension, Series B |
| Lapam Capital | Series A Extension, Series A |
| China Investment Corporation | Series B |
| Unicorn Capital Partners | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 50% MoM.
- Jun 20, 2026
Monthly visitors increased 138% MoM, reaching 2.7K.
Recent news
Latest coverage and updates
- hiresAug 17, 2026
LTZ Therapeutics Inc. hired Phillip Lee as Chief Financial Officer on Aug 17th '26.
- is_developingAug 17, 2026
LTZ Therapeutics Inc. is developing Universal Myeloid Cell Engager Platform.
- is_developingJul 7, 2026
LTZ Therapeutics Inc. is developing IND application for LTZ-232 to treat advanced metastatic colorectal cancer and other solid tumors on Jul 7th '26.
- is_developingJul 7, 2026
LTZ Therapeutics Inc. is developing U-MCE Platform on Jul 7th '26.
LTZ Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about LTZ Therapeutics's valuation, stock price, and market status.
Is LTZ Therapeutics a public or private company?
LTZ Therapeutics is a private company.
What is the current stock price of LTZ Therapeutics?
LTZ Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is LTZ Therapeutics worth (valuation)?
Valuation information for LTZ Therapeutics is not publicly available.
Can I buy LTZ Therapeutics stock?
LTZ Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was LTZ Therapeutics's last funding round?
LTZ Therapeutics's most recent funding round was Early Funding on May 6, 2026.
Who are the main investors in LTZ Therapeutics?
Key investors in LTZ Therapeutics include Boyu Capital, Hillhouse Investment, Lapam Capital, 险峰K2VC, Qiming Venture Partners.
Will LTZ Therapeutics IPO soon?
No public IPO plans have been announced for LTZ Therapeutics.
How can I track LTZ Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor LTZ Therapeutics's secondary market activity and sign up for updates.